An FDA Part 15 psychedelics hearing is not a delivery rule

Tonight at 8:59 P.M. Pacific, the comment window on FDA docket FDA-2026-N-7542 closes. The Part 15 hearing was September 14. What is still open — and only until 11:59 P.M. Eastern on Monday, October 5 — is the written record FDA asked for on how psychedelic drugs might be used therapeutically in supervised and supportive settings.

I have already heard people talk about that record like FDA just wrote the clinic model.

It did not.

The instrument is a Part 15 public hearing and a request for comments. Federal Register, July 14, 2026, 91 FR 43095. Primary notice: https://www.federalregister.gov/documents/2026/07/14/2026-14155/considerations-for-potential-future-therapeutic-use-of-psychedelic-drugs-public-hearing-request-for. Comment portal: Regulations.gov, docket FDA-2026-N-7542. Hearing page: https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/considerations-potential-future-therapeutic-use-psychedelic-drugs-public-hearing-09142026.

A Part 15 file is information-gathering. It is not a proposed rule. It is not a REMS. It is not rescheduling. It is not an approval. Soft talk about credentialing and diversion still gets quoted later as if the industry already signed off on a choke point. That is the part that should keep operators awake tonight.

What FDA actually opened

FDA asked for views in four places: provider training and credentialing, patient safety, access and reimbursement, and data collection. Breakthrough Therapy designations and priority vouchers already floating around this space are not findings of safety or effectiveness. FDA has said that out loud. Treat this docket the same way. Input. Not law.

In April, Executive Order 14401 — Accelerating Medical Treatments for Serious Mental Illness — told HHS and FDA to push access to psychedelic treatments for serious mental illness. Research models. Approvals. Data sharing. Real-world evidence. That order is about getting care to people who need it. A Part 15 record that hardens into boutique-only delivery fights that order. It does not serve it.

Three mistakes I keep hearing

"The hearing is basically a REMS." No. A REMS, if one ever attaches to an approved product, is product-specific. Tonight is a comment file. Do not let soft supervision language get filed in your head as mandatory overnight suites for every indication.

"If we comment, we are on an approval path — or somehow closer to rescheduling." No. Nothing in this docket green-lights a clinic model, a facilitator license, a payor code, or a Schedule change. Approvals still run on product evidence. Scheduling is its own fight. What tonight can do is shape how hard delivery looks after the first approvals land.

"Access is the speech. The rest is details." No. If every session needs a rare credential stack, suite hours no community clinic can staff, and months of prior auth with no coding path, access was a press release. Workforce, space, scheduling, and who can bill are the real constraints. Overbuild those now and the first approvals serve coastal research markets. Veterans, rural patients, and safety-net systems wait. That is the opposite of a national priority for serious mental illness.

Those four buckets FDA named are where the overbuild usually hides.

Training should follow the work. Screening is not the same job as preparation, and neither is the same as sitting with someone through an acute session or doing follow-up the next week. Counselors, nurses, and peer support already staff behavioral health. Shut them out of non-prescriber roles for a tiny specialty club and you get waitlists on day one. Credentialing belongs with state boards and the licenses people already hold. FDA can publish competencies. It should not invent a federal therapist license by another name, and it should not hand the market to one private certifier that also sells the only ticket in.

Consent has to be plain. Expected effects. Distress. Power imbalance. Touch policies. Emergency plans. Screen for cardiovascular disease, psychosis risk, and suicidality. That is medicine. Put it in labeling, in any REMS when a product actually warrants one, and in clinic SOPs. Do not use Part 15 talk to justify one monitoring script for every patient. Set and setting matter. They are not a blank check for spa economics. Match monitoring to product, dose, indication, and patient. Diversion controls for an approved drug should look like other controlled therapeutics — storage, prescribing, accountability — not Schedule I theater that treats every licensed clinic like a crime scene.

FDA does not write payor policy. It does decide how hard delivery is through labeling, any REMS, and the tone of this record. Build with capacity in mind from day one. Clear visit definitions. Evidence packages payors can use. Telehealth for prep and follow-up when that is clinically sound. Security rules that work in a community site, not only a flagship research center.

Common data is useful. Registries and real-world evidence can support what the Executive Order asked for. Adverse-event definitions have to fit acute psychedelic effects and longer-term outcomes without treating expected transient experiences as automatic reportable disasters that punish honest clinics. Start lean. Expand later. Mandates only big health systems can fund freeze smaller providers out and bias the evidence toward whoever already had the money.

What I would do before 8:59 P.M. Pacific

If you touch this lane, file something short and specific on Regulations.gov before the window closes. Say whether you run or build toward supervised care. Say whether exclusive credentialing, maximal monitoring, or a data tax would shut your model out. Point at the Executive Order and ask FDA to keep this record in its lane — hearing input, not shadow rulemaking.

Comment here before the window closes: File a comment on FDA-2026-N-7542 at Regulations.gov

Ask yourself the boring questions. Did FDA open a Part 15 comment file, or did FDA publish a final rule that locks delivery? Does your compliance deck treat "FDA is talking about supervised settings" as "FDA already decided only boutique clinics can deliver," when the July notice is still a request for comments and tonight is still a comment clock?

Read 91 FR 43095. Comment tonight if you have standing to care. Then wait for the product-specific decisions — labeling, any REMS, approvals — before you tell a client the federal delivery floor moved.

This is not legal advice. Thynk Industries is not a law firm. Deadlines move; check the live docket.

If you want a second set of eyes before you file, or help tracking adjacent clocks in this lane, reach out at https://www.thynk.guru/contact-us. If keeping compliance ops straight across wellness products and sites is the headache, that is the kind of work https://thynkflow.io is for.